First patient treated in the Phase III ECHO-301 study
The first patient has been treated in the ECHO-301 study – a Phase III trial evaluating Incyte’s IDO1 inhibitor, epacadostat, with Merck’s Keytruda (pembrolizumab) as first-line treatment for patients with advanced or metastatic melanoma.
Click on this link for more information.
